Skip to main content
Erschienen in: Abdominal Radiology 12/2020

18.09.2020 | Pelvis

Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer

verfasst von: Qiong Zou, Ju Jiao, Min-hong Zou, Ming-zhao Li, Ting Yang, Lei Xu, Yong Zhang

Erschienen in: Abdominal Radiology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The prognostic value of baseline tumor burden of prostate cancer was rarely studied. We aimed to evaluate the whole-body tumor burden of 68Ga- prostate specific membrane antigen-HBED-CC (68Ga-PSMA-11) PET/CT in newly diagnosed prostate cancer semi-automatically, and explore its preliminary application in predicting prognosis.

Methods

Similar to metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of 18F-FDG PET/CT, 68Ga-PSMA-11 PET/CT tumor burden parameters including whole-body PSMA tumor volume (wbPSMA-TV) and whole-body total lesions PSMA uptake (wbTL-PSMA) were acquired semi-automatically. The intra-observer and inter-observer reliability was analyzed. The relationship between tumor burden and prostate-specific antigen (PSA) value or Gleason score was investigated. The preliminary application of tumor burden in predicting progression-free survival (PFS) was explored.

Results

Fifty-nine newly diagnosed prostate cancer patients were retrospectively analyzed. Semi-automatic quantification of whole-body tumor burden had excellent intra-observer and inter-observer consistency [all intra-class correlation coefficient (ICC) > 0.990]. wbPSMA-TV and wbTL-PSMA were 32.6 (range 1.0–3968.2) cm3 and 161.9 (range 6.0–24971.7), respectively. wbPSMA-TV and wbTL-PSMA correlated with PSA (r = 0.858, p < 0.001; r = 0.879, p < 0.001) and Gleason score (r = 0.793, p < 0.001; r = 0.805, p < 0.001) significantly. In univariate analysis, wbPSMA-TV, wbTL-PSMA, SUVmax, SUVpeak, SUVmean, PSMA-TV, TL-PSMA of primary tumor, fPSA and Gleason score were independent significant predictors of PFS (all p < 0.05). Moreover, in multivariate analysis, wbTL-PSMA [hazard ratio (HR): 1.001, p = 0.014] and Gleason score (HR: 5.124, p = 0.031) can significantly predict progression-free prognosis.

Conclusions

As imaging biomarkers, wbPSMA-TV and wbTL-PSMA correlated with clinical characteristics significantly. High wbTL-PSMA or Gleason score was associated with shorter PFS of newly diagnosed prostate cancer independently.
Literatur
1.
2.
Zurück zum Zitat Roberto Iacovelli, Emilie Lanoy, Laurence Albiges et al (2012) Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 110:1747-1753CrossRefPubMed Roberto Iacovelli, Emilie Lanoy, Laurence Albiges et al (2012) Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 110:1747-1753CrossRefPubMed
3.
Zurück zum Zitat Hua-Xiang Xu, Tao Chen, Wen-Quan Wang et al (2014) Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging 41:1093-1102CrossRef Hua-Xiang Xu, Tao Chen, Wen-Quan Wang et al (2014) Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging 41:1093-1102CrossRef
4.
Zurück zum Zitat Eder M, Schäfer M, Bauder-Wüst U et al (2012) 68 Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688-697CrossRefPubMed Eder M, Schäfer M, Bauder-Wüst U et al (2012) 68 Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688-697CrossRefPubMed
5.
Zurück zum Zitat Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen(PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539CrossRefPubMed Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen(PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539CrossRefPubMed
6.
Zurück zum Zitat Ross JS, Sheehan CE, Fisher HA el al (2003) Correlation of primary tumor prostate specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357-6362PubMed Ross JS, Sheehan CE, Fisher HA el al (2003) Correlation of primary tumor prostate specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357-6362PubMed
7.
Zurück zum Zitat Uprimny C, Kroiss AS, Decristoforo C et al (2017) 68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 44:941- 949CrossRefPubMed Uprimny C, Kroiss AS, Decristoforo C et al (2017) 68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 44:941- 949CrossRefPubMed
8.
Zurück zum Zitat Shagera QA, Cheon GJ, Koh Y et al (2019) Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging 46:1417-1427CrossRefPubMed Shagera QA, Cheon GJ, Koh Y et al (2019) Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging 46:1417-1427CrossRefPubMed
9.
Zurück zum Zitat Salavati A, Duan F, Snyder BS et al (2017) Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 44:1969-1983CrossRefPubMedPubMedCentral Salavati A, Duan F, Snyder BS et al (2017) Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 44:1969-1983CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Groheux D, Martineau A, Teixeira L et al (2017) 18FDG-PET/CT for predicting the outcome in ER +/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Res 19:3CrossRefPubMedPubMedCentral Groheux D, Martineau A, Teixeira L et al (2017) 18FDG-PET/CT for predicting the outcome in ER +/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Res 19:3CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Chen HH, Chiu NT, Su WC et al (2012) Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264:559-566CrossRefPubMed Chen HH, Chiu NT, Su WC et al (2012) Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264:559-566CrossRefPubMed
12.
Zurück zum Zitat Kim CY, Hong CM, Kim DH et al (2013) Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging 40:1321-1329CrossRefPubMed Kim CY, Hong CM, Kim DH et al (2013) Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging 40:1321-1329CrossRefPubMed
13.
Zurück zum Zitat Zer A, Domachevsky L, Rapson Y et al (2016) The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer. Eur Radiol 26:3155-3161CrossRefPubMed Zer A, Domachevsky L, Rapson Y et al (2016) The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer. Eur Radiol 26:3155-3161CrossRefPubMed
14.
Zurück zum Zitat Gafita A, Bieth M, Krönke M et al (2019) qPSMA: Semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68 Ga-PSMA11 PET/CT. J Nucl Med 60:1277-1283CrossRefPubMedPubMedCentral Gafita A, Bieth M, Krönke M et al (2019) qPSMA: Semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68 Ga-PSMA11 PET/CT. J Nucl Med 60:1277-1283CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Schmuck S, von Klot CA, Henkenberens C et al (2017) Initial experience with volumetric 68 Ga PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 58:1962-1968CrossRefPubMed Schmuck S, von Klot CA, Henkenberens C et al (2017) Initial experience with volumetric 68 Ga PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med 58:1962-1968CrossRefPubMed
16.
Zurück zum Zitat Schmidkonz C, Cordes M, Schmidt D et al (2018) 68 Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 45:1862-1872CrossRefPubMed Schmidkonz C, Cordes M, Schmidt D et al (2018) 68 Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging 45:1862-1872CrossRefPubMed
17.
Zurück zum Zitat Brito AET, Mourato FA, de Oliveira RPM et al (2019) Evaluation of whole-body tumor burden with 68 Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med 33:344–350 Brito AET, Mourato FA, de Oliveira RPM et al (2019) Evaluation of whole-body tumor burden with 68 Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med 33:344–350
18.
Zurück zum Zitat EderM, Neels O, Müller M et al (2014) Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7:779–796 EderM, Neels O, Müller M et al (2014) Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7:779–796
19.
Zurück zum Zitat Hirata K, Kobayashi K, Wong KP et al (2014) A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One 9:e105682CrossRefPubMedPubMedCentral Hirata K, Kobayashi K, Wong KP et al (2014) A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLoS One 9:e105682CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Kobayashi K, Hirata K, Yamaguchi S et al (2015) Prognostic value of volume-based measurements on (11)C- methionine PET in glioma patients. Eur J Nucl Med Mol Imaging 42:1071-1080CrossRefPubMed Kobayashi K, Hirata K, Yamaguchi S et al (2015) Prognostic value of volume-based measurements on (11)C- methionine PET in glioma patients. Eur J Nucl Med Mol Imaging 42:1071-1080CrossRefPubMed
21.
Zurück zum Zitat Kurtz DM, Green MR, Bratman SV et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125:3679-3687CrossRefPubMedPubMedCentral Kurtz DM, Green MR, Bratman SV et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125:3679-3687CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Bieth M, Kronke M, Tauber R et al (2017) Exploring new multimodal quantitative imaging indices for the assessment of osseous tumor burden in prostate cancer using 68 Ga-PSMA PET/CT. J Nucl Med 58:1632-1637CrossRefPubMed Bieth M, Kronke M, Tauber R et al (2017) Exploring new multimodal quantitative imaging indices for the assessment of osseous tumor burden in prostate cancer using 68 Ga-PSMA PET/CT. J Nucl Med 58:1632-1637CrossRefPubMed
23.
Zurück zum Zitat Ulmert D, Kaboteh R, Fox JJ et al (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62:78-84CrossRefPubMedPubMedCentral Ulmert D, Kaboteh R, Fox JJ et al (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62:78-84CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Etchebehere EC, Araujo JC, Fox PS et al (2015) Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med 56:1177-1184CrossRefPubMed Etchebehere EC, Araujo JC, Fox PS et al (2015) Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med 56:1177-1184CrossRefPubMed
25.
Zurück zum Zitat Matthias Eiber, Ken Herrmann, Jeremie Calais et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA‐ligand PET/CT. J Nucl Med 59:469-478CrossRefPubMed Matthias Eiber, Ken Herrmann, Jeremie Calais et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA‐ligand PET/CT. J Nucl Med 59:469-478CrossRefPubMed
26.
Zurück zum Zitat Hammes J, Tager P, Drzezga A et al (2018) EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT. J Nucl Med 59:1070-1075CrossRefPubMed Hammes J, Tager P, Drzezga A et al (2018) EBONI: A tool for automated quantification of bone metastasis load in PSMA PET/CT. J Nucl Med 59:1070-1075CrossRefPubMed
27.
Zurück zum Zitat Fendler WP, Eiber M, Beheshti M et al (2017) 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol imaging 44:1014-1024CrossRefPubMed Fendler WP, Eiber M, Beheshti M et al (2017) 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol imaging 44:1014-1024CrossRefPubMed
Metadaten
Titel
Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer
verfasst von
Qiong Zou
Ju Jiao
Min-hong Zou
Ming-zhao Li
Ting Yang
Lei Xu
Yong Zhang
Publikationsdatum
18.09.2020
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 12/2020
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02745-7

Weitere Artikel der Ausgabe 12/2020

Abdominal Radiology 12/2020 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.